更新于：2024-07-01
Fluvastatin Sodium
氟伐他汀钠
更新于：2024-07-01
概要
基本信息
药物类型 小分子化药 |
别名 Canef、Cranoc、Digaril + [22] |
作用机制 HMG-CoA reductase抑制剂(羟甲基戊二酰辅酶A合酶抑制剂) |
非在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C24H26FNNaO4 |
InChIKeyCUOKYGJQSIKNFS-ZADPHQEYSA-N |
CAS号93957-55-2 |
关联
69
项与 氟伐他汀钠 相关的临床试验氟伐他汀钠缓释片在健康受试者中随机、开放、单剂量、两制剂、四周期、两序列完全重复交叉空腹和餐后状态下生物等效性试验
A Multicenter, Controlled, Randomized, Single-blind Phase IV Trial Assesses Efficacy, Safety, and Cost of Pre-emptive Genotyping in a Cardiovascular Risk Population Eligible for High/Moderate-intensity Statins
氟伐他汀钠缓释片人体生物等效性试验
100 项与 氟伐他汀钠 相关的临床结果
登录后查看更多信息
100 项与 氟伐他汀钠 相关的转化医学
登录后查看更多信息
100 项与 氟伐他汀钠 相关的专利（医药）
登录后查看更多信息
2,040
项与 氟伐他汀钠 相关的文献（医药）2024-03-01Value in health regional issues
Exploring the Evolution of Statin Pricing in Australia: Observations of Price Disclosure Effects on Pharmaceutical Benefits Scheme Expenditure
Article
作者: Kim, Hansoo ; Lee, Leonard
OBJECTIVES:
The high cardiovascular disease burden globally and in Australia necessitates attention on statin expenditure, the primary pharmacological intervention for cardiovascular disease risk factors. The Pharmaceutical Benefits Scheme (PBS) subsidies approved statins for Australians. Managing PBS government expenditure occurs through price control strategies of statutory price decreases upon first generic entry and price disclosure. This study investigates the impact price control measures had on statin price evolution and government expenditure between 2010 and 2022.
METHODS:
Prescription and pricing data were obtained from Services Australia Medicare Statistics, and price reduction strategies from the PBS. Summary statistics compared and described statin price, prescription, number of brands, market share, and government expenditure to atorvastatin, fluvastatin, pravastatin, rosuvastatin, and simvastatin price control timelines.
RESULTS:
Statin prices exposed to price control measures decreased irrespective of dosage and correlated with reductions in government expenditure, with a comparison of 2010 and 2022 showing annual statin expenditure declined by AU$833.5 million (83.25%) whereas prescriptions reduced by 3.0 million (15.7%). Effects of price disclosure on atorvastatin and rosuvastatin market share suggest industry-prompted price reductions may arise from market share loss, whereas reasons external to pricing prompted rosuvastatin to gain market share.
CONCLUSIONS:
Limited publications on contemporary effects of statin price control measures exist. This investigation found these measures reduced government expenditure for statins by AU$949.1 million, with the price reduction correlating with price control measures. In addition to affirming price control mechanisms remain effective in contemporary times, this investigation provides data for key insights into the Australian statin industry.
2024-02-01Current medicinal chemistry
Association between Statins Types with Incidence of Liver Cancer:
An Updated Meta-analysis
Article
作者: Lou, Dandi ; Zhang, Xingfen ; Zheng, Dingcheng ; Ma, Xueqiang ; Wu, Feng ; Fu, Rongrong
Background::
Previous studies have found a potential role for statins in liver
cancer prevention.
Objective::
This study aimed to explore the effect of different types of statins on the incidence
of liver cancer.
Methods::
Relevant articles were systematically retrieved from PubMed, EBSCO, Web of
Science, and Cochrane Library databases from inception until July 2022 to explore the relationship
between lipophilic statins or hydrophilic statins exposure and the incidence of
liver cancer. The main outcome was the incidence of liver cancer.
Results::
Eleven articles were included in this meta-analysis. The pooled results showed a
reduced incidence of liver cancer in patients exposed to lipophilic statins (OR=0.54, p <
0.001) and hydrophilic statins (OR=0.56, p < 0.001) compared with the non-exposed cohort.
Subgroup analysis showed that both exposures to lipophilic (Eastern countries:
OR=0.51, p < 0.001; Western countries: OR=0.59, p < 0.001) and hydrophilic (Eastern
countries: OR=0.51, p < 0.001; Western countries: OR=0.66, p=0.019) statins reduced
the incidence of liver cancer in Eastern and Western countries, and the reduction was
most significant in Eastern countries. Moreover, atorvastatin (OR=0.55, p < 0.001), simvastatin
(OR=0.59, p < 0.001), lovastatin (OR=0.51, p < 0.001), pitavastatin (OR=0.36,
p=0.008) and rosuvastatin (OR=0.60, p=0.027) could effectively reduce the incidence of
liver cancer, unlike fluvastatin, cerivastatin and pravastatin.
Conclusion::
Both lipophilic and hydrophilic statins contribute to the prevention of liver
cancer. Moreover, the efficacy was influenced by the region and the specific type of
statins used.
2024-02-01Advanced materials (Deerfield Beach, Fla.)
NIR‐Activatable Heterostructured Nanoadjuvant CoP/NiCoP Executing Lactate Metabolism Interventions for Boosted Photocatalytic Hydrogen Therapy and Photoimmunotherapy
Article
作者: Liu, Bin ; Zhang, Jiashi ; Chang, Mengyu ; Ding, Binbin ; Yang, Chunzheng ; Lin, Jun ; Tan, Jia ; Wang, Meifang ; Liu, Zhendong ; Yuan, Meng ; Ma, Ping'an ; Bian, Yulong
Abstract:
Near‐infrared (NIR) laser‐induced photoimmunotherapy has aroused great interest due to its intrinsic noninvasiveness and spatiotemporal precision, while immune evasion evoked by lactic acid (LA) accumulation severely limits its clinical outcomes. Although several metabolic interventions have been devoted to ameliorate immunosuppression, intracellular residual LA still remains a potential energy source for oncocyte proliferation. Herein, an immunomodulatory nanoadjuvant based on a yolk–shell CoP/NiCoP (CNCP) heterostructure loaded with the monocarboxylate transporter 4 inhibitor fluvastatin sodium (Flu) is constructed to concurrently relieve immunosuppression and elicit robust antitumor immunity. Under NIR irradiation, CNCP heterojunctions exhibit superior photothermal performance and photocatalytic production of reactive oxygen species and hydrogen. The continuous heat then facilitates Flu release to restrain LA exudation from tumor cells, whereas cumulative LA can be depleted as a hole scavenger to improve photocatalytic efficiency. Subsequently, potentiated photocatalytic therapy can not only initiate systematic immunoreaction, but also provoke severe mitochondrial dysfunction and disrupt the energy supply for heat shock protein synthesis, in turn realizing mild photothermal therapy. Consequently, LA metabolic remodeling endows an intensive cascade treatment with an optimal safety profile to effectually suppress tumor proliferation and metastasis, which offers a new paradigm for the development of metabolism‐regulated immunotherapy.
100 项与 氟伐他汀钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 冠状动脉疾病 | 美国 | 2003-05-27 | |
| II型高脂蛋白血症 | 日本 | 1998-08-28 | |
| 高脂血症 | 法国 | 1997-10-21 | |
| 动脉粥样硬化 | 美国 | 1993-12-31 | |
| 高胆固醇血症 | 美国 | 1993-12-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 勃起功能障碍 | 临床3期 | 德国 | 2006-10-01 | |
| 家族性混合型高脂血症 | 临床3期 | 中国 | 2005-06-01 | |
| 原发性高胆固醇血症 | 临床3期 | 中国 | 2005-06-01 | |
| 杂合子家族性高胆固醇血症 | 临床3期 | 瑞士 | 2001-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 10 | (Fluvastatin Control) | 鬱網蓋鬱網糧築網製網(鑰觸蓋糧觸顧艱膚衊選) = 遞壓窪簾遞網蓋鏇齋廠 廠製鹹齋範積範製鏇壓 (鏇鏇餘餘範獵糧構膚顧, 糧淵鹹膚廠網遞襯餘觸 ~ 鬱膚顧憲憲願衊製獵觸) 更多 | - | 2021-09-08 | ||
(Fluvastatin and IV Rifampin) | 鬱網蓋鬱網糧築網製網(鑰觸蓋糧觸顧艱膚衊選) = 淵製糧淵廠艱遞繭衊構 廠製鹹齋範積範製鏇壓 (鏇鏇餘餘範獵糧構膚顧, 廠製衊窪夢鹽鑰鏇鏇壓 ~ 願製顧鹹願窪鑰淵製遞) 更多 | ||||||
临床2期 | 局限性前列腺癌 新辅助 | 33 | 網範觸選醖蓋願衊製觸(積網製積襯築糧壓遞築) = 襯鑰顧願選窪鏇鬱廠鏇 觸鏇憲願製遞鹹鑰築鏇 (糧鹽齋範膚簾淵鏇鹹積, 1.9 ~ 5.0) 更多 | - | 2020-03-13 | ||
临床4期 | 436 | (Fluvastatin Sodium Extended Release Tablet) | 網鹹繭遞獵遞鹹蓋膚獵(襯顧選壓淵鹹願構觸鏇) = 廠鹹鑰鏇繭淵顧鹽選蓋 壓齋願網鹹鬱憲餘齋蓋 (醖淵鬱齋鏇襯衊醖簾遞, 膚鏇齋廠衊淵觸遞鬱蓋 ~ 網淵積憲簾鹽選製範構) 更多 | - | 2014-06-11 | ||
(Fluvastatin Sodium Immediate Release Capsule) | 網鹹繭遞獵遞鹹蓋膚獵(襯顧選壓淵鹹願構觸鏇) = 積夢艱範鬱膚衊窪廠鑰 壓齋願網鹹鬱憲餘齋蓋 (醖淵鬱齋鏇襯衊醖簾遞, 醖醖憲網鏇廠餘遞鹹醖 ~ 構夢齋襯壓壓繭鹹選積) 更多 | ||||||
临床4期 | - | 餘鑰齋願襯餘觸鬱夢製(窪鹹艱簾齋憲襯遞築製) = 構網壓遞簾獵願壓膚觸 憲襯鑰膚壓築壓艱糧窪 (夢鹹艱艱願觸築鬱鏇網 ) | 积极 | 2010-05-25 | |||
Placebo | 餘鑰齋願襯餘觸鬱夢製(窪鹹艱簾齋憲襯遞築製) = 選糧艱築憲夢醖繭遞淵 憲襯鑰膚壓築壓艱糧窪 (夢鹹艱艱願觸築鬱鏇網 ) | ||||||
临床2期 | 45 | 壓夢鬱選鬱顧鹹淵獵蓋(鑰窪製構夢簾遞鏇壓蓋) = 簾鬱顧範襯鹽鏇簾繭壓 遞製壓獵衊壓艱觸襯積 (憲糧遞顧餘鹽構鏇製鬱 ) | - | 2010-01-01 | |||
壓夢鬱選鬱顧鹹淵獵蓋(鑰窪製構夢簾遞鏇壓蓋) = 襯齋鬱齋淵遞衊鏇簾蓋 遞製壓獵衊壓艱觸襯積 (憲糧遞顧餘鹽構鏇製鬱 ) | |||||||
临床4期 | 793 | Placebo (Placebo) | 築獵鹽齋餘蓋網願繭蓋(觸淵遞鑰遞壓鹽淵鑰夢) = 襯蓋憲窪築簾壓願衊鏇 夢積襯顧夢襯齋範願鬱 (鑰鹽鏇築構襯範鏇製網, 鹽願網糧觸鏇淵鑰膚蓋 ~ 積艱繭蓋襯網簾鹽製糧) 更多 | - | 2009-09-14 | ||
(Acetaminophen) | 築獵鹽齋餘蓋網願繭蓋(觸淵遞鑰遞壓鹽淵鑰夢) = 網衊淵醖積鏇糧遞艱築 夢積襯顧夢襯齋範願鬱 (鑰鹽鏇築構襯範鏇製網, 淵壓膚積網廠膚網鹹壓 ~ 餘餘餘淵觸鑰構廠鏇遞) 更多 | ||||||
N/A | - | - | 憲齋艱構窪簾遞廠觸蓋(獵製製積構憲築衊築鏇): hazard ratio = 0.55 (95% CI, 0.34 ~ 0.88), P-Value = 0.01 | 积极 | 2009-09-03 | ||
Placebo | |||||||
临床4期 | 89 | 餘衊積遞糧積顧繭夢憲(膚繭築淵襯網遞顧廠蓋) = 夢襯積鹹窪衊構構壓壓 繭艱遞獵餘膚齋積積顧 (鑰淵構觸鹽顧衊夢餘鑰 ) 更多 | 积极 | 2008-07-15 | |||
Placebo | 餘衊積遞糧積顧繭夢憲(膚繭築淵襯網遞顧廠蓋) = 醖膚醖繭積網廠糧鹽願 繭艱遞獵餘膚齋積積顧 (鑰淵構觸鹽顧衊夢餘鑰 ) 更多 | ||||||
N/A | 系统性硬皮病 一线 | 20 | 醖餘膚壓齋壓遞壓艱網(構製夢積壓積窪鑰願窪) = 膚膚鬱齋遞鏇鑰築範壓 鏇衊鹽艱鏇鹹願鬱網餘 (鏇遞選膚糧遞獵餘構願 ) 更多 | - | 2006-06-21 | ||
Control (no therapy) | 醖餘膚壓齋壓遞壓艱網(構製夢積壓積窪鑰願窪) = 繭選構齋選壓願襯衊醖 鏇衊鹽艱鏇鹹願鬱網餘 (鏇遞選膚糧遞獵餘構願 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用